Skip Navigation

European Heart Journal 2002 23(11):835-837; doi:10.1053/euhj.2001.3133
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moliterno, D.J.
Right arrow Articles by Topol, E.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moliterno, D.J.
Right arrow Articles by Topol, E.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Hotline Editorials

The TARGET trial: hit or miss?

D.J. Moliterno and E.J. Topol

Department of Cardiovascular Medicine and C5 (Cleveland Clinic Cardiovascular Coordinating Center), The Cleveland Clinic Foundation, Cleveland, OH, U.S.A.

References

  1. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
  2. N Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
  3. Lancet. 1998;352:87–92[Web of Science][Medline]
  4. Lancet. 1997;349:1422–1428[CrossRef][Web of Science][Medline]
  5. Circulation. 1997;96:1445–1453[Abstract/Free Full Text]
  6. Lancet. 2000;356:2037–2044[CrossRef][Web of Science][Medline]
  7. Moliterno D, Topol E. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. Am Heart J. 2000;140:722–726[CrossRef][Web of Science][Medline]
  8. Topol E, Moliterno D, Herrmann H. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–1894[Abstract/Free Full Text]
  9. Cadroy Y, Bossavy J-P, Thalamas C. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000;101:2823–2828[Abstract/Free Full Text]
  10. Klinkhardt U, Kirchmaier C, Westrup D. Ex vivo– in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A. Clin Pharmacol Ther. 2000;67:305–313[CrossRef][Web of Science][Medline]
  11. Steinhubl S, Ellis S, Wolski K, Lincoff A, Topol E. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation. 2001;103:1403–1409[Abstract/Free Full Text]
  12. Gilchrist I, Oshea J, Kosoglou T. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 2001;104:406–411[Abstract/Free Full Text]
  13. Simon D, Liu G, Ganz P. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Cathet Cardiovasc Intervent. 2001;52:433–434[Medline]
  14. Steinhubl S, Talley J, Braden G. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001;103:2572–2578[Abstract/Free Full Text]
  15. Cannon C, Weintraub W, Demopoulos L. Comparison of an early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1939–1942[Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moliterno, D.J.
Right arrow Articles by Topol, E.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moliterno, D.J.
Right arrow Articles by Topol, E.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?